(Pilot Program) The main goal of the proposed Center's Pilot Program is to foster the career development of junior investigators carrying out research in the field of cystic fibrosis (CF). A secondary goal is to attract more senior investigators from outside the field into areas of CF research. One mechanism that has been key to achieving these goals is our Pilot Program, which provides seed money for research that has not yet reached the stage of maturity necessary to garner funding through traditional NIH mechanisms. During the 21 years that the P30 Pilot Program has been running, it has funded 66 pilots in areas of CF research and other genetic diseases. Numerous junior investigators funded through this program have gone onto develop independent and well funded research programs. Prior to 2014, P30 Pilots included other genetic diseases and after that they were required to be focused on CF (including lung). In keeping with the overall shift of the Center's focus for this funding cycle, revisions to the Pilot Program include a requirement for the research to be focused on CF research related to the NIDDK mission (i.e., excluding lung). The Pilot Program is run through the Center's Administrative Core, with oversight from three committees: the Pilot and Feasibility Committee, the Executive Committee, and the External Advisory Committee. These groups take into account two external reviews per application in making decisions about funding. Progress of the pilot projects is monitored through numerous forums that are supported by the Center's Enrichment Program, and awardees are provided with extensive, constructive feedback that greatly facilitates the evolution of their research. In this section, we will summarize the progress made in past pilot projects and the success that many of the pilot holders have had to date. Notably, the 7 pilot grants that were funded during the last 5-year funding period resulted in 25 publications.
| Gray, Robert D; Hardisty, Gareth; Regan, Kate H et al. (2018) Delayed neutrophil apoptosis enhances NET formation in cystic fibrosis. Thorax 73:134-144 |
| Rosen, Bradley H; Chanson, Marc; Gawenis, Lara R et al. (2018) Animal and model systems for studying cystic fibrosis. J Cyst Fibros 17:S28-S34 |
| Diehl, Lauri; Meyerholz, David K; Day, Michael J et al. (2018) Pathology and Pathogenesis of Immune-Mediated Diseases of Animals. Vet Pathol 55:5-7 |
| Caswell, Jeff L; Bassel, Laura L; Rothenburger, Jamie L et al. (2018) Observational Study Design in Veterinary Pathology, Part 2: Methodology. Vet Pathol 55:774-785 |
| Trillo-Muyo, Sergio; Nilsson, Harriet E; Recktenwald, Christian V et al. (2018) Granule-stored MUC5B mucins are packed by the non-covalent formation of N-terminal head-to-head tetramers. J Biol Chem 293:5746-5754 |
| Yoshida, Mitsuteru; Oishi, Hisashi; Martinu, Tereza et al. (2018) Pentraxin 3 deficiency enhances features of chronic rejection in a mouse orthotopic lung transplantation model. Oncotarget 9:8489-8501 |
| Thornell, Ian M; Li, Xiaopeng; Tang, Xiao Xiao et al. (2018) Nominal carbonic anhydrase activity minimizes airway-surface liquid pH changes during breathing. Physiol Rep 6: |
| Clippinger, Amy J; Allen, David; Behrsing, Holger et al. (2018) Pathway-based predictive approaches for non-animal assessment of acute inhalation toxicity. Toxicol In Vitro 52:131-145 |
| Cheng, Sunny Lihua; Li, Xueshu; Lehmler, Hans-Joachim et al. (2018) Gut Microbiota Modulates Interactions Between Polychlorinated Biphenyls and Bile Acid Homeostasis. Toxicol Sci 166:269-287 |
| Cooney, Ashley L; McCray Jr, Paul B; Sinn, Patrick L (2018) Cystic Fibrosis Gene Therapy: Looking Back, Looking Forward. Genes (Basel) 9: |
Showing the most recent 10 out of 669 publications
